Advertisement
Advertisement
Advertisement

Recurrent Deep Vein Thrombosis and Two Coagulation Factor Gene Mutations: Quo Vadis?

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 1999: 82/6 (Dec) pp.1562-1783
Pages: 1564-1567

Recurrent Deep Vein Thrombosis and Two Coagulation Factor Gene Mutations: Quo Vadis?

Anthonie W. A. Lensing (1) , Martin H. Prins (2)
From the (1) Centre for Vascular Medicine, and the (2) Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, The Netherlands

Summary

In the past decades considerable progress has been made in the understanding of inherited and acquired causes of venous thrombosis and their clinical impact (1). Thus, the risk of a first venous thrombosis is approximately 10-fold increased in subjects with deficiency of antithrombin, protein C or S (1, 2), 7-fold increased in patients with cancer (3), or the antiphospholipid antibody syndrome (4, 5), and 3 to 5-fold in carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene (6-8). All together, these conditions can be identified in more than 50% of patients with a first episode of venous thrombosis (1, 2, 8).

Thrombosis News

Mobile technology identifies people with unknown atrial fibrillation at high risk of stroke – article published in Thrombosis and Haemostasis

The article “Feasibility and cost effectiveness of stroke prevention through community screening...

TH 111.4

The April 2014 TH 111.4 issue of Thrombosis and Haemostasis is a Theme Issue by Guest Editor B....

TH 111.3

Women with atrial fibrillation have a much higher risk for thromboembolic stroke than men suffering...